Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Navio MD vs Spry

Navio MD
Graded #128

Higher grade

vs+12.700000000000003
Spry
Graded #409

Lower grade

The verdict

Navio MD takes it — 69.5/100 to 56.8/100.

Navio MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NavioMD offers compounded tirzepatide ($247/mo) plus brand-name Ozempic ($1,199/mo) and Mounjaro ($1,249/mo).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNavio MD +2
56
54
Dose & formulationNavio MD +13
77
64
Clinical oversightNavio MD +32
87
55
Labs & monitoringNavio MD +2
54
52
FulfillmentNavio MD +24
85
61
Contract termsEven
55
55
Navio MD · left barSpry · right bar

The numbers

MetricNavio MDSpry
WeighScore69.5/10056.8/100
GradeCC
Scorecard rank#128#409
Semaglutide$345/mo (starting dose, brand-name)$199/mo (starting dose, compounded)
Tirzepatide$189/mo (starting dose, compounded)$299/mo (starting dose, compounded)
Coverage48 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Navio MD

Graded #128 · C

Strengths

  • LegitScript verified with board-certified providers and US-licensed pharmacies
  • Both compounded and brand-name options
  • 48-state coverage
  • Hours 9am–10pm EST Mon–Sun
  • Transparent tiered pricing: you only pay for your current dose

Where it loses points

  • Not available in Alabama and Mississippi
  • Compounded option is tirzepatide only — no compounded semaglutide listed
  • Also offers women's HRT (broader platform)
  • Pricing is tiered by dose ('as low as'); the entry prices climb as your dose increases
Spry

Graded #409 · C

Strengths

  • Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
  • Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
  • Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
  • No contracts or commitment required
  • LegitScript Certified with a public verification link

Where it loses points

  • Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
  • Intake reviewed by a nurse practitioner, not an MD
  • States served not disclosed publicly
  • Pharmacy partner not named, and 503A vs 503B designation not specified
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard